Antifungal and antiviral products of marine organisms.
Antifungal and antiviral products of marine organisms.
复制标题
DOI：
10.1007/s00253-014-5575-0
复制
发表时间：
2014-04
影响因子：
5
通讯作者：
Ng TB
中科院分区：
文献类型：
--
作者：
Cheung RC;Wong JH;Pan WL;Chan YS;Yin CM;Dan XL;Wang HX;Fang EF;Lam SK;Ngai PH;Xia LX;Liu F;Ye XY;Zhang GQ;Liu QH;Sha O;Lin P;Ki C;Bekhit AA;Bekhit Ael-D;Wan DC;Ye XJ;Xia J;Ng TB
海洋生物，包括细菌、真菌、藻类、海绵、棘皮动物、软体动物和头壳动物，产生各种具有抗真菌活性的产品，包括细菌几丁质酶、脂肽和内酯；真菌(−)-菌核素和多肽、海绵中的紫杉醇B和C、贝克德曼B和紫杉醇；藻类冈比亚果酸A和B、植物单宁；去甲肾上腺素、溴酪氨酸生物碱、双吲哚生物碱、沉胶酮B和(−)-沉胶酮D、卤代胺、金龟子G、海藻糖苷A和烷基苯磺酸酯；软体动物多糖Kahalalide F和具有SRSELIVHQR序列的1485Da的多肽；从海洋生物中提取的抗病毒化合物包括细菌多糖和呋喃-2-乙酸乙酯；真菌大环内酯类化合物、紫杉酯A、紫醌B、异吲哚酮衍生物、交替三醇Q、四氢交替醇C和抗菌素A、海藻二萜、木糖乳糖呋喃、藻酸、糖脂磺基喹诺酮二酰甘油、硫化多糖p-KG03、分生二萜、钒藻酸甲酯衍生物、凝集素、多糖、单宁、杀菌素、花青素、去甲叉花萜和辣椒素；壳聚糖类抗脂多糖因子、大球藻糖苷三萜、海藻糖苷B、金鱼藤素A和B；以及海参皂苷1-5(1-5)、海参皂苷1-5(1-5)、海参皂苷1-5(1-5)、沙棘花素1-5(1-5)、沙棘花素1-5(1-5)、沙棘花素1-5(1-5)、沙棘木素1-5、毛花青素和斑点花青素。虽然仅有部分上述化合物的抗真菌和抗病毒作用机制已被阐明，但将那些已知具有明显不同机制、良好的生物利用度和毒性最小的化合物用于联合治疗的可能性仍有待研究。测试海洋抗菌剂与现有药物的协同作用也是值得的。鉴于海洋生物中含有丰富的这些化合物，它们在临床上的应用前景是光明的。这些化合物还可用于农业和食品工业。
Marine organisms including bacteria, fungi, algae, sponges, echinoderms, mollusks, and cephalochordates produce a variety of products with antifungal activity including bacterial chitinases, lipopeptides, and lactones; fungal (−)-sclerotiorin and peptaibols, purpurides B and C, berkedrimane B and purpuride; algal gambieric acids A and B, phlorotannins; 3,5-dibromo-2-(3,5-dibromo-2-methoxyphenoxy)phenol, spongistatin 1, eurysterols A and B, nortetillapyrone, bromotyrosine alkaloids, bis-indole alkaloid, ageloxime B and (−)-ageloxime D, haliscosamine, hamigeran G, hippolachnin A from sponges; echinoderm triterpene glycosides and alkene sulfates; molluscan kahalalide F and a 1485-Da peptide with a sequence SRSELIVHQR; and cepalochordate chitotriosidase and a 5026.9-Da antifungal peptide. The antiviral compounds from marine organisms include bacterial polysaccharide and furan-2-yl acetate; fungal macrolide, purpurester A, purpurquinone B, isoindolone derivatives, alterporriol Q, tetrahydroaltersolanol C and asperterrestide A, algal diterpenes, xylogalactofucan, alginic acid, glycolipid sulfoquinovosyldiacylglycerol, sulfated polysaccharide p-KG03, meroditerpenoids, methyl ester derivative of vatomaric acid, lectins, polysaccharides, tannins, cnidarian zoanthoxanthin alkaloids, norditerpenoid and capilloquinol; crustacean antilipopolysaccharide factors, molluscan hemocyanin; echinoderm triterpenoid glycosides; tunicate didemnin B, tamandarins A and B and; tilapia hepcidin 1–5 (TH 1–5), seabream SauMx1, SauMx2, and SauMx3, and orange-spotted grouper β-defensin. Although the mechanisms of antifungal and antiviral activities of only some of the afore-mentioned compounds have been elucidated, the possibility to use those known to have distinctly different mechanisms, good bioavailability, and minimal toxicity in combination therapy remains to be investigated. It is also worthwhile to test the marine antimicrobials for possible synergism with existing drugs. The prospects of employing them in clinical practice are promising in view of the wealth of these compounds from marine organisms. The compounds may also be used in agriculture and the food industry.